In the complex landscape of mental health research, a new peer-reviewed viewpoint offers a critical examination of how genes and environment conspire to influence schizophrenia risk. Published in Genomic Psychiatry (ISSN: 2997-2388, Genomic Press, New York), this thought-provoking analysis by researchers Natassia Robinson and Sarah E.
Misha Kudryshev's lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia.
In a comprehensive review of recent genetic and population studies, published in the peer-reviewed medical journal Genomic Psychiatry (Genomic Press, New York), Professors Michael Owen and Michael O'Donovan of Cardiff University's Centre for Neuropsychiatric Genetics and Genomics present evidence that challenges conventional wisdom about cognitive deficits in schizophrenia
Neurodevelopmental and psychiatric disorders (NPD) including schizophrenia, bipolar disorder, autism, and depression are detrimental to individuals, their families and society as a whole, and in many cases still lack effective treatments.
According to a study, dyslexia and ADHD are unique from developmental and mental health diseases like autism, bipolar disorder, and schizophrenia since they share many genes and frequently co-occur in individuals.
